VBI-S

DRUG2 trials

Sponsors

Vivacelle Bio

Conditions

HypovolemiaSepsisSeptic Shock

Phase 2

VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients

Vivacelle BioHypovolemia, Sepsis, Septic Shock

Start: 2020-02-17End: 2023-12-31Updated: 2023-10-23

Phase 3

A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)

RecruitingNCT06072430

Vivacelle BioHypovolemia, Sepsis, Septic Shock

Start: 2024-08-06End: 2025-12-31Target: 46Updated: 2025-04-04

Related Papers

Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2a clinical pilot trial.

2024-01-293 citations